Brad Johnson is the Director of Purification Development at Thermo Fisher Scientific’s Princeton, NJ, and St. Louis, MO, USA facilities. Dr. Johnson has over 20 years’ experience designing and developing downstream purification processes for Phase I to Phase III biologic drugs, including monoclonal antibodies and recombinant proteins. He has led both process development and manufacturing teams, and has expertise in developing processes for complex proteins, including glycoproteins, multi-subunit proteins, and coagulation factors. He graduated with a Ph.D. in Microbiology and Molecular Genetics from the University of Texas Health Science Center at Houston.